Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A controlled clinical study of standard-of-care therapy alone versus standard-of-care plus Pelareorep in second-line KRAS-Mutant Microsatellite-Stable metastatic colorectal cancer

Next Previous
Trial Profile

A controlled clinical study of standard-of-care therapy alone versus standard-of-care plus Pelareorep in second-line KRAS-Mutant Microsatellite-Stable metastatic colorectal cancer

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 17 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pelareorep (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Oncolytics Biotech

Most Recent Events

  • 17 Feb 2026 New trial record
  • 04 Feb 2026 According to a Oncolytics Biotech media release, company plans to initiate controlled clinical study in KRAS-Mutant Microsatellite-Stable metastatic colorectal cancer and first clinical site is expected to be activated in March, with up to 10 additional sites anticipated to open soon thereafter.Interim data are expected by year-end. The study design and milestone details to be provided soon.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top